^
KDR C482R
Clear Cell Renal Cell Carcinoma
crizotinib + pazopanib
Sensitive
:
C3
Onco Targets Ther - 3d
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive
:
B
Merck (MSD) Press Release - 4d
No biomarker
RCC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive
:
A1
PD-L1 expression
RCC
avelumab + axitinib
Sensitive
:
A1
No biomarker
RCC
avelumab + axitinib
Sensitive
:
A1
No biomarker
RCC
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
RCC
Zirabev (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
RCC
sorafenib
Sensitive
:
A1
No biomarker
RCC
tivozanib
Sensitive
:
A1
No biomarker
RCC
temsirolimus
Sensitive
:
A1
No biomarker
RCC
sunitinib
Sensitive
:
A1
No biomarker
RCC
everolimus + lenvatinib
Sensitive
:
A1
No biomarker
RCC
everolimus
Sensitive
:
A1
No biomarker
RCC
bevacizumab + pegylated interferon α -2a
Sensitive
:
A1
No biomarker
RCC
cabozantinib tablet
Sensitive
:
A1
No biomarker
RCC
pembrolizumab + axitinib
Sensitive
:
A1
No biomarker
RCC
nivolumab
Sensitive
:
A1
No biomarker
RCC
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
Sensitive
:
A1
No biomarker
RCC
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
RCC
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
RCC
axitinib
Sensitive
:
A1
No biomarker
RCC
pazopanib
Sensitive
:
A1
No biomarker
RCC
aldesleukin
Sensitive
:
A1
No biomarker
RCC
Bevax (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
RCC
bevacizumab
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our